No Data
No Data
RBC Capital Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $181
Tuesday Market Pulls Back After Nvidia All Time High | Wall Street Today
Market Sells CES Tech News, ISM Tuesday as Nvidia Champions Robots Monday | Live Stock
Johnson & Johnson Drug Combination Shows Positive Results in Lung Cancer Study
Johnson & Johnson Announces RYBREVANT Plus LAZCLUZE Show Statistically Significant And Clinically Meaningful Improvement In Overall Survival Versus Osimertinib; Median Overall Survival Improvement Expected To Exceed One Year; First And Only Regimen...
Express News | J&J: Rybrevant Plus Lazcluze Shows Statistically Significant & Clinically Meaningful Improvement in Overall Survival Vs Osimertinib